Perioperative Management of Hypertensive Patients

Helsi Rismiati; Hae-Young Lee

doi:10.36011/cpp.2021.3.e7

Journal List > Cardiovasc Prev Pharmacother > v.3(3) > 1516079383

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Rismiati and Lee: Perioperative Management of Hypertensive Patients

Review Article

Cardiovasc Prev Pharmacother 2021;3(3):54-63.

Published online: 31 July 2021

DOI: https://doi.org/10.36011/cpp.2021.3.e7

Perioperative Management of Hypertensive Patients

Helsi Rismiati, MD

, Hae-Young Lee, MD, PhD

Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea

Correspondence to Hae-Young Lee, MD, PhD Department of Internal Medicine, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul 03080, Korea. E-mail: hylee612@snu.ac.kr

Received 22 July 2021 Accepted 31 July 2021

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Due to the high prevalence of hypertension, hypertensive patients undergo perioperative evaluation and management. Severe hypertension may increase the operative risk. However, hypertension with a diastolic blood pressure of less than 110 mmHg usually does not appear to increase the risk. In general, it is recommended that oral antihypertensive drugs be continued before and after surgery. In particular, sympathetic blockers, such as beta-blockers, should be maintained. It is generally recommended to continue intake of calcium channel blockers, especially for surgeries with a low bleeding risk. However, in the case of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, it is recommended that they be stopped 24 hours before surgery because they can inhibit excessive compensatory renin-angiotensin activation during surgery. Statin and aspirin medications are often prescribed for patients with hypertension. It is recommended to continue intake of statins in the perioperative period. Aspirins are recommended for low-risk patients undergoing noncardiac surgery.

Go to :

Keywords: Hypertension, Perioperative care, Surgery

INTRODUCTION

Hypertension (HT) affects most adults and is steeply increasing in the elderly population across the globe.1)2) The prevalence of HT as an individual cardiovascular risk factor in patients aged 45 years or older undergoing non-cardiac surgery has temporally increased from 52% in 2004–2005 to 63% in 2012–2013 in the US.3)

Nearly half of all patients undergoing surgery take medications for chronic, noncommunicable diseases.4) The majority of medications are cardiovascular drugs, accounting for 48% of all drugs.4) HT is the most common comorbidity, being the reason for up to 27% of postponed surgeries.5) Frequently, hypertensive patients experience intraoperative blood pressure (BP) lability, which can lead to myocardial ischemia in the worst-case scenario.6) In a meta-analysis of 30 observational studies, HT preceding operative procedures was associated with a 35% increase in cardiovascular complications7); therefore, proper perioperative management is required.8) This review aims at summarizing perioperative risk stratification and management of hypertensive patients undergoing surgery.

Go to :

PERIOPERATIVE RISK STRATIFICATION OF HYPERTENSIVE PATIENTS

During the induction of anesthesia, sympathetic nerve activation may increase BP by 20 to 30 mmHg and heart rate by 15 to 20 times per minute in normal subjects and may cause a more exaggerated response in hypertensive patients.9) The average arterial pressure decreases with the passage of anesthesia time, and BP and heart rate slowly increase as the anesthesia wanes immediately after surgery.9)

Hypertensive patients are more likely to experience BP fluctuations during the operation, which may lead to myocardial ischemia.6) European guidelines recommend that perioperative BP be maintained at 70–100% of the baseline to prevent excessive tachycardia.6) The perioperative risk associated with HT varies depending on HT stage. However, most evidence regarding BP level and perioperative risk was from clinical studies prior to 1990, when there were few antihypertensive medications. It is also unclear whether postponing surgery to control BP in hypertensive patients can reduce this risk.

The most validated clinical risk index, known as the Revised Cardiac Risk Index (RCRI), includes 6 factors, each worth 1 score (Table 1).10) The results showed risk estimates of myocardial infarction, ventricular fibrillation or cardiac arrest, pulmonary edema, and complete heart block of 0.5% (95% confidence interval [CI], 0.2–1.1%) for an RCRI score of 0, 1.3% (95% CI, 0.7–2.1%) for an RCRI score of 1, 3.6% (95% CI, 2.1–5.6%) for an RCRI score of 2, and 9.1% (95% CI, 5.5–13.8%) for an RCRI score ≥3.10) The RCRI showed moderate discrimination in predicting major perioperative cardiac complications in a large sample systematic review.11) The RCRI stratified patients with low-risk (<1%) and higher risk (≥1%) for perioperative major adverse cardiovascular events during surgical hospital admission or within 30 days of surgery. Although HT itself is not considered as a main component of RCRI, HT requiring medication was counted as one of the 21 preoperative components to predict postoperative complications in the American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP).12) Although the ACS NSQIP surgical risk calculator is more complex than RCRI, it may provide better predictive discrimination.13)

Table 1.

The clinical risk indices before undergoing noncardiac surgery modified from the Revised Cardiac Risk Index10)

Six predictors of cardiac complication before undergoing noncardiac surgery		Score
	High-risk type of surgery (abdominal, thoracic, or vascular surgery above the groin level)	1
	Ischemic heart disease (positive exercise load test, history of myocardial infarction, chest pain suspected of angina pectoris, presence of pathological Q wave on electrocardiogram, or use of nitrate therapy)	1
	History of heart failure	1
	History of cerebrovascular disease	1
	Diabetes requiring insulin treatment	1
	Serum creatinine concentration before surgery ≥2 mg/dL	1
	Total	6
Estimated risk of perioperative major cardiovascular complication according to summed scores
	Score 0	<1%
	Score 1	1–2%
	Score 2	2–6%
	Score ≥3	>6%

Perioperative risk is divided into two categories according to the stage of HT. One is severe HT, in which case it is recommended that the surgery be postponed.6) Severe HT is defined as high systolic/diastolic BP ≥180/110 mmHg, new identification of HT-mediated organ damage, or suspicion of secondary HT without proper diagnosis.6) Patients with severe HT who did not take antihypertensive medication showed an exaggerated BP change during induction and operative procedures.14)15) In other studies, preoperative diastolic BP >110 mmHg has been associated with various complications such as arrhythmia, myocardial ischemia, myocardial infarction, and heart failure; therefore, it is reasonable to recommend surgery after controlling BP.16)17)

In contrast, in patients with mild to moderate HT with systolic/diastolic BP <180/110 mmHg, there is no evidence of the benefit of postponing surgery to optimize therapy.6)7) HT with a diastolic BP of less than 110 mmHg does not appear to increase the risk of surgery.6) Therefore, it is safe to recommend that BP be carefully monitored during and after the operation without delaying the surgery.

Go to :

PERIOPERATIVE MANAGEMENT OF HYPERTENSIVE PATIENTS TAKING ANTIHYPERTENSIVE MEDICATION

In principle, oral antihypertensive drugs should be continued until the point of surgery. Beta-blockers or clonidine, in particular, can cause severe repulsive BP rise if abruptly stopped before surgery.18-20) It is recommended that most antihypertensive medications be taken with a small amount of water, even on the morning of surgery. However, in the case of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs), it is recommended to stop them for 24 hours before surgery.21) The recent recommendation guidelines and evidence of antihypertensive medications are presented in Figure 1 and summarized in Table 2. The following is a summary of the recommendations for antihypertensive drugs in each group.

Figure 1.

Perioperative antihypertensive medicine summary.

ACEIs = angiotensin-converting enzyme inhibitors; ARBs = angiotensin receptor blockers.

^*Initiate more than one day before surgery and start with drug titration for intermediate-high-risk patients, patients with ischemic heart disease or myocardial ischemia, or with revised cardiac risk index factors ≥3; ^†Discontinue ACEIs or ARBs before non-cardiac surgery in hypertensive patients. However, in stable patients with heart failure and left ventricular systolic dysfunction, continuing these drugs should be considered; ^‡Continue receiving aspirin in patients with moderate- to high-risk cardiovascular events undergoing non-cardiac surgery; ^§Withhold aspirin 7–10 days before surgery in low-risk patients undergoing noncardiac surgery. Aspirin is started when the risk of bleeding has passed (8–10 days after major non-cardiac surgery). Individualized maintenance in patients with previous cardiovascular interventions.

Table 2.

Summary recommendation for perioperative management of anti-hypertensive patients

Medicine class	Indication	Perioperative management	Class of recommendation	Reference
Beta-blockers (β-blockers)	Continue	Continue without interruption among patients taking the drug chronically.	IB	ESC/ESA, ACC/AHA, CCS Guidelines6)21)22)
Beta-blockers (β-blockers)	Initiate	Initiate more than one day before surgery and start with drug titration for intermediate-high risk patients, patients with ischemic heart disease or myocardial ischemia, or with RCRI factors ≥3.	IIB	ESC/ESA, ACC/AHA Guidelines6)22)
ACEIs or ARBs	Discontinue	Discontinue ACEIs or ARBs before non-cardiac surgery in hypertensive patients.	IIA	ACC/AHA Guidelines22)
	Continue	Continue ACEIs or ARBs, under close monitoring, during non-cardiac surgery in stable patients with heart failure and left ventricular systolic dysfunction.	IIA	ACC/AHA Guidelines22)
	Withhold	Withhold ACEIs or ARBs starting 24 hours before non-cardiac surgery in patients treated chronically with ACEIs or ARBs.	IIA	ESC/ESA, ACC/AHA, CCS Guidelines6)21)22)
Calcium channel blockers	Continue	Continue the non-dihydropyridine calcium channel blockers in patients who do not tolerate beta-blockers. Additionally, continue calcium channel blockers during non-cardiac surgery in patients with vasospastic angina.	Expert opinion	ESC/ESA, ACC/AHA Guidelines6)21)22)
Calcium channel blockers	Do not Initiate	Not recommended for the prevention of perioperative cardiovascular events.	Expert opinion	CCS Guidelines21)
Diuretics	Withhold	Withhold on the day of surgery unless there is volume overload or congestive heart failure.	Expert opinion	ACCF/AHA, Cygan, and Waitzki. Tagawa, Ogata, and Hamano23-25)
Statin	Continue	Continue statin among patients currently taking statin.	I	ESC/ESA, ACC/AHA Guidelines6)22)
Statin	Initiate	Initiate statin at least 2 weeks before surgery in patients undergoing vascular surgery.	IIA	ESC/ESA Guidelines6)
Aspirin	Continue	Continue administering aspirin in patients with moderate- to high-risk cardiovascular events undergoing non-cardiac surgery.	IIC	ACCP Guidelines26)
	Continue	Continue in patients undergoing carotid endarterectomy and patients with recent coronary artery stent and	IIC	CCS Guidelines21)
	Withhold	Withhold aspirin 7–10 days pre-surgery in low-risk patients undergoing non-cardiac surgery.	IIC	ACCP Guidelines26)
	Withhold	Restart aspirin when the risk of bleeding has passed (8–10 days after major non-cardiac surgery).	IIC	CCS Gudelines21)

ACC = American College of Cardiology; ACCF = American College of Cardiology Foundation; ACCP = American College of Chest Physicians; ACEIs = angiotensinconverting enzyme inhibitors; AHA = American Heart Association; AHA = American Heart Association; ARBs = angiotensin receptor blockers; CCS = Canadian Cardiovascular Society; ESA = European Society of Anaesthesiology; ESC = European Society of Cardiology; RCRI = Revised Cardiac Risk Index.

Beta-blockers

Beta-blockers are standard therapy for congestive heart failure, HT, ischemic heart disease, and arrhythmia disease.1)2)6)22) Beta-receptors in the human body consist of three subtypes: β1-, β2-, and β3-receptors. β1-receptors are predominant in cardiac tissue. Stimulation of these receptors increases cardiac output by causing positive chronotropic and inotropic effects.27) β2-receptors are found particularly in the smooth muscles of vascular and pulmonary tissue.27) They induce vasodilation and bronchodilation in the heart and cause myocytes to increase heart rate and contractility. β3-receptors are located in adipose tissue and skeletal muscle, and their activation causes lipolysis and thermogenesis.27) In the case of beta-blockers, bisoprolol and atenolol, which have high beta-1 selectivity, are preferentially recommended to prevent bronchoconstriction during surgery.28-30)

There is a consensus that hypertensive patients should continue beta-blocker medication when undergoing surgery.22) According to a nationwide cohort study by Andersson et al.,31) beta-blockers have the advantage of reducing the risk of major adverse cardiac events within 30 days of follow-up after surgery among patients with myocardial ischemia who underwent non-cardiac surgery. They equally reduce mortality among those with heart failure and recent myocardial infarction. Beta-blockers have been reported to reduce myocardial ischemia and myocardial infarction during non-cardiac surgery in multiple meta-analyses.32-35) Betablockers significantly reduce atrial fibrillation and ventricular arrhythmias within 30 days of follow-up after surgery and may have little or no effect on bradycardia and hypotension.36)37) Therefore, their intake should be continued during surgery. In particular, in patients with coronary artery disease, sudden discontinuation of beta-blockers before surgery can cause angina pectoris, myocardial infarction, or sudden death.

There is still controversy regarding whether adding new beta-blockers before surgery will be helpful. It has been reported in particular that adding high-dose beta-blockers immediately before surgery increases the risk of mortality, in part because of the higher incidence of stroke, hypotension, and bradycardia.38) Therefore, if beta-blockers are added to high-risk patients, it is recommended to start with a margin of at least 24 hours before surgery and adjust the dose with an adaptation period, preferably for a week or so.13) If repeated, starting new beta-blockers on the morning of the surgery should be avoided.

ACEIs/ARBs

It is recommended to withhold ACEIs and ARBs for 24 hours before surgery unless it is difficult to stop the medication due to heart failure or severe HT.6)21) This recommendation is because long-term hypotension can be induced if the compensatory action of the reninangiotensin system is inhibited during surgery.39)40) Indeed, this recommendation is in conjunction with recent prospective international cohort studies, the Vascular Events In Noncardiac Surgery Patients Cohort Evaluation (VISION) study.41) The VISION study included 16,079 patients aged >45 years from 8 countries: Asian, Australian, European, North, and South American from 2007 to 2011.41) This cohort showed evidence that patients who took ACEIs/ARBs at baseline, then withheld their ACEIs/ARBs in the 24 hours prior to surgery had an 18% relative risk reduction of the composite outcome of death, stroke, and myocardial injury after non-cardiac surgery, compared to patients who continued the medication (relative risk, 0.82; 95% CI, 0.70–0.96; p=0.01).41) A recent meta-analysis pooled 13 published papers (3 randomized control trials and 10 observational studies) which showed that patients who continued consuming the ACEIs/ARBs were significantly prone to developing hypotension when under anesthesia, with a relative risk of 41%.42) Usually, it is recommended to take the ACEIs or ARBs until the morning of the day before surgery, to stop intake on the day of surgery, and resume intake the day after surgery if the vital signs are stable.21) On the other hand, it is recommended to continue intake for as long as possible in the case of heart failure patients, even during surgery, and restart as soon as possible, if intake was stopped.6)

Despite the recommendations mentioned earlier, the American College of Cardiology/ American Heart Association (ACC/AHA) guidelines indicate that it is reasonable to continue ACEI or ARB therapy; this differs from the recommendations of the European and Canadian Guidelines.22) This recommendation was based on a large observational retrospective study of 79,228 patients who underwent non-cardiac surgery and was analyzed with propensity score matching between patients on ACEIs and those not on ACEIs.43) In this matched cohort study, there was no association between ACEI administration and respiratory morbidity after surgery as the primary outcome and no association with 30-day mortality and composite in-hospital mortality and morbidity as a secondary outcome; however, intraoperative hypotension was more common in patients taking ACEIs.43) This study included patients with low-risk and highrisk surgeries, while other previous studies were limited to high-risk surgeries.43) This study suggests that it is reasonable to continue ACEI medication for minor risk surgeries.

Calcium channel blockers

In the case of calcium blockers, the incidence of postoperative bleeding may be increased by inhibiting platelet aggregation, and bleeding may worsen by interfering with compensatory vasoconstriction.44) Nevertheless, it is recommended to continue intake because the benefits of BP control outweigh the damage.6)

Diuretics

In a recent observational study by Tagawa et al.,23) evaluating 2,725 subjects who underwent noncardiac surgery, perioperative diuretic administration was associated with a risk of postoperative acute kidney injury by 2.07 (95% CI, 1.10–3.89; p=0.02). There is no consistent recommendation on whether diuretics should be withheld before surgery. However, it is usually recommended to withhold them on the day of surgery if the risk of BP elevation is low.45) It was reported that withholding diuretics on the day of surgery reduced the risk of acute kidney injury.23)

Statins and aspirin

Statins and aspirin are frequently prescribed medications for patients with hypertension. The perioperative use of statins is suggested to have a beneficial effect. A meta-analysis of 35 randomized control trials, including 8,200 patients, showed that statin therapy has a protective effect on postoperative myocardial infarction in non-cardiac surgery by 64% (odds ratio, 0.44; 95% CI, 0.3–0.64).46) Therefore, statins should be continued in those on treatment. Moreover, statins should be initiated at least 2 weeks before surgery in patients undergoing vascular surgery or in patients with clinical risk factors undergoing an elevated-risk procedure.47-49)

Aspirin use in the perioperative period remains a contentious debate. The Perioperative Ischemic Evaluation 2 trial was a multinational, randomized controlled trial (RCT) that observed the outcome of 10,010 patients undergoing non-cardiac surgery on low-dose aspirin vs. placebo.50) The patients were stratified according to the 5,628 patients with aspirin initiation and 4,382 patients with aspirin continuation.50) Aspirin did not reduce mortality or non-fatal myocardial infarction rates at 30 days follow-up after non-cardiac surgery.50) However, major bleeding was more common in the aspirin group than in the placebo group. The primary and secondary results were comparable in either the initiation or continuation aspirin group.50) Therefore, it is not recommended to initiate or continue aspirin use during non-cardiac surgery. In contrast, in a RCT with 220 subjects, with at least one cardiac risk factor, undergoing high-to-intermediate risk non-cardiac surgery, treatment with low-dose aspirin seven days before surgery and three days post-surgery, compared to placebo, reduced the absolute and relative risks of post-surgery major adverse cardiovascular events by 7.2% and 80% respectively. Notably, there was no increase in perioperative bleeding between the aspirin and placebo groups (median perioperative estimated blood loss: 300 mL vs. 300 mL, p=0.61).51)

The American College of Chest Physicians (ACCP) guidelines recommend withholding aspirin 7–10 days prior to low-risk, non-cardiac surgery.26) In contrast, moderate to high-risk patients undergoing non-cardiac surgery are recommended to continue aspirin around the time of surgery.26) The Canadian Cardiovascular Society Guidelines recommend withholding aspirin at least 3 days prior to surgery, except for patients who undergo carotid endarterectomy and for patients after recent coronary stent implantation. It is equally recommended to restart aspirin intake when the period for bleeding risk related to surgery has passed.21)

Go to :

CONCLUSION

Severe HT ≥180/110 mmHg can increase the risk of surgery. Therefore, sufficient BP control prior to the surgery is recommended. In general, oral hypertensive medication should be continued before and after surgery. In particular, sympathetic blockers, such as beta-blockers, must be continued. However, it is recommended to stop taking ACEI and ARB 24 hours before surgery because they can inhibit excessive compensatory renin-angiotensin activation during surgery. It is strongly recommended to continue with statins during surgery, whereas it is recommended to withhold aspirin in order to minimize the risk of bleeding.

Go to :

Notes

Conflict of Interest

The authors have no financial conflicts of interest.

Author Contributions

Conceptualization: Rismiati H, Lee HY; Supervision: Lee HY; Writing - original draft: Rismiati H; Writing - review & editing: Rismiati H, Lee HY.

Go to :

REFERENCES

1. Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I. 2018 ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). G Ital Cardiol (Rome). 2018; 19 Suppl 1:3S–73S.

2. Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B; Zannad F; Task Force Members. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013; 31:1281–357.

3. Smilowitz NR, Gupta N, Guo Y, Beckman JA, Bangalore S, Berger JS. Trends in cardiovascular risk factor and disease prevalence in patients undergoing non-cardiac surgery. Heart. 2018; 104:1180–6.

4. Kennedy JM, van Rij AM, Spears GF, Pettigrew RA, Tucker IG. Polypharmacy in a general surgical unit and consequences of drug withdrawal. Br J Clin Pharmacol. 2000; 49:353–62.

5. Dix P, Howell S. Survey of cancellation rate of hypertensive patients undergoing anaesthesia and elective surgery. Br J Anaesth. 2001; 86:789–93.

6. Kristensen SD, Knuuti J, Saraste A, Anker S, Bøtker HE, De Hert S, Ford I, Gonzalez Juanatey JR, Gorenek B, Heyndrickx GR, Hoeft A, Huber K, Iung B, Kjeldsen KP, Longrois D, Luescher TF, Pierard L, Pocock S, Price S, Roffi M, Sirnes PA, Uva MS, Voudris V, Funck-Brentano C; Authors/Task Force Members. 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: the joint task force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). Eur J Anaesthesiol. 2014; 31:517–73.

7. Casadei B, Abuzeid H. Is there a strong rationale for deferring elective surgery in patients with poorly controlled hypertension? J Hypertens. 2005; 23:19–22.

8. Venkatesan S, Myles PR, Manning HJ, Mozid AM, Andersson C, Jørgensen ME, Hardman JG, Moonesinghe SR, Foex P, Mythen M, Grocott MPW, Sanders RD. Cohort study of preoperative blood pressure and risk of 30-day mortality after elective non-cardiac surgery. Br J Anaesth. 2017; 119:174.

9. Wolfsthal SD. Is blood pressure control necessary before surgery? Med Clin North Am. 1993; 77:349–63.

10. Lee TH, Marcantonio ER, Mangione CM, Thomas EJ, Polanczyk CA, Cook EF, Sugarbaker DJ, Donaldson MC, Poss R, Ho KK, Ludwig LE, Pedan A, Goldman L. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. Circulation. 1999; 100:1043–9.

11. Ford MK, Beattie WS, Wijeysundera DN. Systematic review: prediction of perioperative cardiac complications and mortality by the revised cardiac risk index. Ann Intern Med. 2010; 152:26–35.

12. Bilimoria KY, Liu Y, Paruch JL, Zhou L, Kmiecik TE, Ko CY, Cohen ME. Development and evaluation of the universal ACS NSQIP surgical risk calculator: a decision aid and informed consent tool for patients and surgeons. J Am Coll Surg. 2013; 217:833–842. e1.

13. Smilowitz NR, Berger JS. Perioperative cardiovascular risk assessment and management for noncardiac surgery: a review. JAMA. 2020; 324:279–90.

14. Prys-Roberts C, Greene LT, Meloche R, Foëx P. Studies of anaesthesia in relation to hypertension. II. Haemodynamic consequences of induction and endotracheal intubation. Br J Anaesth. 1971; 43:531–47.

15. Travieso-Gonzalez A, Núñez-Gil IJ, Riha H, Donaire JAG, Ramakrishna H. Management of arterial hypertension: 2018 ACC/AHA versus ESC Guidelines and perioperative implications. J Cardiothorac Vasc Anesth. 2019; 33:3496–503.

16. Goldman L, Caldera DL. Risks of general anesthesia and elective operation in the hypertensive patient. Anesthesiology. 1979; 50:285–92.

17. Prys-Roberts C, Meloche R, Foëx P. Studies of anaesthesia in relation to hypertension. I. Cardiovascular responses of treated and untreated patients. Br J Anaesth. 1971; 43:122–37.

18. Metz S, Klein C, Morton N. Rebound hypertension after discontinuation of transdermal clonidine therapy. Am J Med. 1987; 82:17–9.

19. Jain AK, Hiremath A, Michael R, Ryan JR, McMahon FG. Clonidine and guanfacine in hypertension. Clin Pharmacol Ther. 1985; 37:271–6.

20. Houston MC. Abrupt cessation of treatment in hypertension: consideration of clinical features, mechanisms, prevention and management of the discontinuation syndrome. Am Heart J. 1981; 102:415–30.

21. Duceppe E, Parlow J, MacDonald P, Lyons K, McMullen M, Srinathan S, Graham M, Tandon V, Styles K, Bessissow A, Sessler DI, Bryson G, Devereaux PJ. Canadian Cardiovascular Society guidelines on perioperative cardiac risk assessment and management for patients who undergo noncardiac surgery. Can J Cardiol. 2017; 33:17–32.

22. Fleisher LA, Fleischmann KE, Auerbach AD, Barnason SA, Beckman JA, Bozkurt B, Davila-Roman VG, Gerhard-Herman MD, Holly TA, Kane GC, Marine JE, Nelson MT, Spencer CC, Thompson A, Ting HH, Uretsky BF, Wijeysundera DN; American College of Cardiology; American Heart Association. 2014 ACC/ AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol. 2014; 64:e77–137.

23. Tagawa M, Ogata A, Hamano T. Pre- and/or intra-operative prescription of diuretics, but not reninangiotensin-system inhibitors, is significantly associated with acute kidney injury after non-cardiac surgery: a retrospective cohort study. PLoS One. 2015; 10:e0132507.

24. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. 2013 ACCF/ AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013; 62:e147–239.

25. Cygan R, Waitzkin H. Stopping and restarting medications in the perioperative period. J Gen Intern Med. 1987; 2:270–83.

26. Douketis JD, Spyropoulos AC, Spencer FA, Mayr M, Jaffer AK, Eckman MH, Dunn AS, Kunz R. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141:e326S–e350S.

27. Pai SL, Chadha RM; Irizarry-Alvarado JM, Renew JR, Aniskevich S 3rd. Pharmacologic and perioperative considerations for antihypertensive medications. Curr Clin Pharmacol. 2017; 12:135–40.

28. Ashes C, Judelman S, Wijeysundera DN, Tait G, Mazer CD, Hare GM, Beattie WS. Selective β1-antagonism with bisoprolol is associated with fewer postoperative strokes than atenolol or metoprolol: a single-center cohort study of 44,092 consecutive patients. Anesthesiology. 2013; 119:777–87.

29. Poldermans D, Boersma E, Bax JJ, Thomson IR, van de Ven LL, Blankensteijn JD, Baars HF, Yo TI, Trocino G, Vigna C, Roelandt JR, van Urk H; Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. N Engl J Med. 1999; 341:1789–94.

30. Wallace AW, Au S, Cason BA. Perioperative β-blockade: atenolol is associated with reduced mortality when compared to metoprolol. Anesthesiology. 2011; 114:824–36.

31. Andersson C, Mérie C, Jørgensen M, Gislason GH, Torp-Pedersen C, Overgaard C, Køber L, Jensen PF, Hlatky MA. Association of β-blocker therapy with risks of adverse cardiovascular events and deaths in patients with ischemic heart disease undergoing noncardiac surgery: a Danish nationwide cohort study. JAMA Intern Med. 2014; 174:336–44.

32. Auerbach AD, Goldman L. Beta-blockers and reduction of cardiac events in noncardiac surgery: scientific review. JAMA. 2002; 287:1435–44.

33. Stevens RD, Burri H, Tramèr MR. Pharmacologic myocardial protection in patients undergoing noncardiac surgery: a quantitative systematic review. Anesth Analg. 2003; 97:623–33.

34. McGory ML, Maggard MA, Ko CY. A meta-analysis of perioperative beta blockade: what is the actual risk reduction? Surgery. 2005; 138:171–9.

35. Bangalore S, Wetterslev J, Pranesh S, Sawhney S, Gluud C, Messerli FH. Perioperative beta blockers in patients having non-cardiac surgery: a meta-analysis. Lancet. 2008; 372:1962–76.

36. Blessberger H, Lewis SR, Pritchard MW, Fawcett LJ, Domanovits H, Schlager O, Wildner B, Kammler J, Steinwender C. Perioperative beta-blockers for preventing surgery-related mortality and morbidity in adults undergoing cardiac surgery. Cochrane Database Syst Rev. 2019; 9:CD013435.

37. Blessberger H, Kammler J, Domanovits H, Schlager O, Wildner B, Azar D, Schillinger M, Wiesbauer F, Steinwender C. Perioperative beta-blockers for preventing surgery-related mortality and morbidity. Cochrane Database Syst Rev. 2018; 3:CD004476.

38. POISE Study Group, Devereaux PJ, Yang H, Yusuf S, Guyatt G, Leslie K, Villar JC, Xavier D, Chrolavicius S, Greenspan L, Pogue J, Pais P, Liu L, Xu S, Málaga G, Avezum A, Chan M, Montori VM, Jacka M, Choi P. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet. 2008; 371:1839–47.

39. Nabbi R, Woehlck HJ, Riess ML. Refractory hypotension during general anesthesia despite preoperative discontinuation of an angiotensin receptor blocker. F1000Res. 2013; 2:12.

40. Kheterpal S, Khodaparast O, Shanks A, O'Reilly M, Tremper KK. Chronic angiotensin-converting enzyme inhibitor or angiotensin receptor blocker therapy combined with diuretic therapy is associated with increased episodes of hypotension in noncardiac surgery. J Cardiothorac Vasc Anesth. 2008; 22:180–6.

41. Roshanov PS, Rochwerg B, Patel A, Salehian O, Duceppe E, Belley-Côté EP, Guyatt GH, Sessler DI, Le Manach Y, Borges FK, Tandon V, Worster A, Thompson A, Koshy M, Devereaux B, Spencer FA, Sanders RD, Sloan EN, Morley EE, Paul J, Raymer KE, Punthakee Z, Devereaux PJ. Withholding versus continuing angiotensin-converting enzyme inhibitors or angiotensin ii receptor blockers before noncardiac surgery: an analysis of the Vascular events In noncardiac Surgery patIents cOhort evaluatioN Prospective Cohort. Anesthesiology. 2017; 126:16–27.

42. Ling Q, Gu Y, Chen J, Chen Y, Shi Y, Zhao G, Zhu Q. Consequences of continuing renin angiotensin aldosterone system antagonists in the preoperative period: a systematic review and meta-analysis. BMC Anesthesiol. 2018; 18:26.

43. Turan A, You J, Shiba A, Kurz A, Saager L, Sessler DI. Angiotensin converting enzyme inhibitors are not associated with respiratory complications or mortality after noncardiac surgery. Anesth Analg. 2012; 114:552–60.

44. Mehta JL. Influence of calcium-channel blockers on platelet function and arachidonic acid metabolism. Am J Cardiol. 1985; 55:158B–164B.

45. Miller RD. Miller's Anesthesia. 8th ed. Philadelphia, PA: Elsevier/Saunders;2015.

46. Putzu A, de Carvalho E Silva CM, de Almeida JP, Belletti A, Cassina T, Landoni G, Hajjar LA. Perioperative statin therapy in cardiac and non-cardiac surgery: a systematic review and meta-analysis of randomized controlled trials. Ann Intensive Care. 2018; 8:95.

47. Sanders RD, Nicholson A, Lewis SR, Smith AF, Alderson P. Perioperative statin therapy for improving outcomes during and after noncardiac vascular surgery. Cochrane Database Syst Rev. 2013; CD009971.

48. Winchester DE, Wen X, Xie L, Bavry AA. Evidence of pre-procedural statin therapy a meta-analysis of randomized trials. J Am Coll Cardiol. 2010; 56:1099–109.

49. Chopra V, Wesorick DH, Sussman JB, Greene T, Rogers M, Froehlich JB, Eagle KA, Saint S. Effect of perioperative statins on death, myocardial infarction, atrial fibrillation, and length of stay: a systematic review and meta-analysis. Arch Surg. 2012; 147:181–9.

50. Devereaux PJ, Mrkobrada M, Sessler DI, Leslie K, Alonso-Coello P, Kurz A, Villar JC, Sigamani A, Biccard BM, Meyhoff CS, Parlow JL, Guyatt G, Robinson A, Garg AX, Rodseth RN, Botto F, Lurati Buse G, Xavier D, Chan MT, Tiboni M, Cook D, Kumar PA, Forget P, Malaga G, Fleischmann E, Amir M, Eikelboom J, Mizera R, Torres D, Wang CY, VanHelder T, Paniagua P, Berwanger O, Srinathan S, Graham M, Pasin L, Le Manach Y, Gao P, Pogue J, Whitlock R, Lamy A, Kearon C, Baigent C, Chow C, Pettit S, Chrolavicius S, Yusuf S; POISE-2 Investigators. Aspirin in patients undergoing noncardiac surgery. N Engl J Med. 2014; 370:1494–503.

51. Oscarsson A, Gupta A, Fredrikson M, Järhult J, Nyström M, Pettersson E, Darvish B, Krook H, Swahn E, Eintrei C. To continue or discontinue aspirin in the perioperative period: a randomized, controlled clinical trial. Br J Anaesth. 2010; 104:305–12.

Go to :

TOOLS

Similar articles